LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
26 funds hold it · Insiders net selling
Net selling: insiders sold $275K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 9, 2026
Period ending
Sep 30, 2026
Earnings per share
$0.26 expected
Estimates as of Nov 13, 2026
EPS expected
$0.33 to $0.45
Revenue expected
8 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 9, 2026 | $0.35est. $0.26 | +35.92%beat | $259.9MSEC filing | +60.7%from $161.7M |
| Jun 30, 2026Reported Aug 3, 2026 | $0.05est. $0.41 | -87.80%miss | $240.3MSEC filing | +70.3%from $141.1M |
| Mar 31, 2026Reported May 6, 2026 | $0.18est. $0.28 | -35.09%miss | $204.9MSEC filing | +69.6%from $120.9M |
| Dec 31, 2025Reported Feb 26, 2026 | $0.14est. $0.35 | -60.00%miss | $192.6MAlpha Vantage | +78.0%from $108.2M |
| Sep 30, 2025Reported Nov 3, 2025 | $0.16est. $0.22 | -26.30%miss | $161.7MSEC filing | +92.8%from $83.9M |
| Jun 30, 2025Reported Aug 4, 2025 | $0.17est. $0.29 | -41.38%miss | $141.1MSEC filing | +92.1%from $73.5M |
| Mar 31, 2025Reported May 5, 2025 | $0.03est. $0.17 | -82.35%miss | $120.9MSEC filing | +90.4%from $63.5M |
| Dec 31, 2024Reported Mar 3, 2025 | $0.15est. $0.09 | +$0.06beat | $108.2MAlpha Vantage | +146.0%from $44.0M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $192.6M | $204.9M | $240.3M | $259.9M |
| Cost of what it sold | $38.1M | $33.5M | $41.2M | $42.1M |
| Gross profit | $154.4M | $171.4M | $199.1M | $217.9M |
| What it spent | ||||
| Research and development | $41.2M | $48.4M | $95.3M | $51.3M |
| Sales and admin | $62.7M | $88.2M | $82.1M | $80.7M |
| Total operating expenses | $103.9M | $136.6M | $177.5M | $132.0M |
| What was left | ||||
| Operating profit | $50.5M | $34.8M | $21.7M | $85.9M |
| Interest on debt | $6.5M | $7.7M | $16.6M | $15.8M |
| Profit before tax | $45.1M | $20.4M | $10.2M | $73.9M |
| Tax | $22.1M | $586.0K | $2.5M | $18.4M |
| Net profit | $23.0M | $19.8M | $7.8M | $55.5M |
| EBITDA | $51.7M | $28.1M | $21.8M | $89.8M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
TG Therapeutics (TGTX) Lifts Revenue Guidance As Investors Ask If The Stock Is Pricey
Leans bearishNov 10TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up
BullishNov 10TG Therapeutics stock hits 52-week high at 63.68 USD
NeutralNov 10TG Therapeutics (TGTX) Q3 2026 Earnings Call Transcript
BullishNov 10TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
BullishNov 9What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call
BullishNov 9TG Therapeutics Releases Q3 2026 Financial Results
BullishNov 9TG Therapeutics Q3 2026 Earnings Call Transcript
BullishNov 9
